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Abstract
Although efficacious forms of malaria chemoprophylaxis currently exist, many travelers to
malaria-endemic areas fail to use them effectively. We suggest that taking antimalarial medications prior
to travel may prevent more malaria by improving compliance. Treatment regimens of antimalarial drugs
taken prior to travel could protect persons for up to one month of exposure. We urge additional testing
of pre-travel malaria chemoprophylaxis regimens.
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Abstract. Although efficacious forms of malaria chemoprophylaxis currently exist, many travelers to malaria-
endemic areas fail to use them effectively. We suggest that taking anti-malarial medications prior to travel may prevent
more malaria by improving compliance. Treatment regimens of antimalarial drugs taken prior to travel could protect
persons for up to one month of exposure. We urge additional testing of pre-travel malaria chemoprophylaxis regimens.
For most Americans, Canadians, Europeans, and Austra-
lians, personal experience with malaria is limited to travel-
related exposure in tropical areas. Imported malaria is vastly
under-reported in the United States; minimum figures from
the U.S. Centers for Disease Control and Prevention indicate
that approximately 1,000 travelers are infected with malaria
in the United States each year.1 Although anti-mosquito mea-
sures such as repellants are also indicated, the primary pre-
ventive measure for international travelers remains taking an-
timalarial drugs during exposure (chemoprophylaxis). Effica-
cious drugs for the chemoprophylaxis of travelers to malaria-
endemic areas already exist. Their effectiveness is seriously
compromised by the human propensity to resist taking medi-
cation when one is not actually ill. Most travelers developing
malaria after return to their home country have been taking
no medication rather than an imperfect one. The problem of
travelers’ malaria cannot be solved by the development of
superior new antimalarial drugs alone; one has to find a better
way to get travelers to actually ingest prescribed medication.
Chemotherapy of any infectious agent is based on the ad-
ministration of full dosages of a drug that kills the organism
and then maintaining adequate blood concentrations for suf-
ficient time to cure the patient. Malaria chemoprophylaxis
depends on maintaining inhibitory drug concentrations over
an entire exposure period such that when an infection occurs,
it is aborted either in the liver or blood prior to the appear-
ance of symptomatic malaria. This works in theory much bet-
ter than practice because any adherence failure by travelers
leaves them unprotected.
Currently, most travelers use some variation of continuous
prophylaxis in which either daily or weekly dosing is given
prior to the start of travel, during travel, and for 1–4 weeks
after return. The use of long-acting drugs given in treatment
doses pre-travel is an alternative strategy that could be known
as pre-exposure prophylaxis. In this setting, a single 1–3-day
treatment regimen is given shortly prior to travel on the basis
that persistent drug levels may protect travelers for up to four
weeks.
Two examples suggest this alternative approach could
prove superior to continuous prophylaxis. Directly observed
therapy (DOT) has revolutionized the treatment of tubercu-
losis not by creating a new therapeutic paradigm, but by en-
suring that the patients really do ingest their medications.2
Intermittent presumptive therapy of malaria either in preg-
nant women (IPTp) or infants (IPTi) is delivering substantial
public health benefits in malaria-endemic areas not by elimi-
nating malaria, but by ensuring that there are periods when
vulnerable populations have full treatment courses of antima-
larial drugs that result in periods without parasitemia.3 We
think it is possible that more travelers would be protected
against malaria if they were able to take a full course of an
efficacious antimalarial drug shortly prior to leaving their
home country as pre-exposure malaria chemoprophylaxis
than by failing to take conventionally prescribed prophylactic
medication. Compliance would be improved because fewer
drug ingestions would be required of travelers and their at-
tention would be focused on potential disease risks before
their actual departure. Issues of counterfeit or expired medi-
cation would be minimized.4 Adverse drug events could be
handled in the traveler’s home country by his or her own
physician. The traveler would be freed to get on with business
or holiday activity without worrying whether the discomforts
inherent in international travel were due to a medication in-
duced adverse event.
All this crucially depends on how long such post-treatment
protection persists. There are published data indicating that
pre-exposure malaria chemoprophylaxis is efficacious.
Chemoprophylaxis and vaccine studies in malaria-endemic
areas often incorporate a course of antimalarial medication to
clear any pre-existing parasitemia. When atovaquone/
proguanil (Malarone; GlaxoSmithKline, Research Triangle,
Park, NC) was used in the high transmission area of western
Kenya in 1997, the first asymptomatic blood infection was
noted 35 days after medication and most infections did not
appear until well into the second month.5 This observation
has been reproduced in the same area during a vaccine study
in 2004 (Polhemous M, unpublished data). Blood stage para-
site challenge infections in Australia have been confounded
by drug-action duration by atovaquone/proguanil persisting
for more than a month.6 Volunteer studies have shown that
atovaquone can inhibit both mosquito stages and blood stages
of malaria for six weeks after drug administration.7 The un-
usually long time that antimalarial action was observed is not
easily explained by the standard understanding of the phar-
macokinetics of atovaquone. We speculate that hepatic elimi-
nation of atovaquone may cause the liver to be a drug reser-
voir not often appreciated by blood concentration measure-
ments.
Even if efficacious, pre-exposure chemoprophylaxis would
not apply to long-term travelers and would be best adopted
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by those traveling for one month or less. Because this time
limitation includes > 95% of international tourists, pre-
exposure malaria chemoprophylaxis could potentially prevent
most travel-related malaria infections. Those whose travel
plans extended beyond their originally anticipated schedule
could take an additional course of medication after leaving
the malaria-endemic area. Because atovaquone/proguanil
may not be an optimal agent to prevent Plasmodium vivax
infection, travelers to areas with substantial exposure to re-
lapsing malaria such as Asia or Oceania could use an 8-ami-
noquinoline such as the long-acting primaquine analog taf-
enoquine, which is currently in advanced development.8
Monthly prophylaxis administration has been shown to be
efficacious with tafenoquine.9 An additional future alterna-
tive may be another very long-acting drug under development
known as piperaquine.10
This approach needs further evidence that could be gener-
ated by deliberate trials to determine the efficacy of post
treatment protection in non-immunes and its duration. Use of
pre-exposure and post-exposure malaria chemoprophylaxis
would not necessarily require the development of new drug
regimens. Existing treatment schedules that already have
large bodies of safety and tolerance data would be used. We
submit that our proposed reversal of indications, using ma-
laria treatment regimens for chemoprophylaxis, would re-
quire additional studies in defined traveler populations but
could be adopted without extensive regulatory changes. More
travelers using effective antimalarial drugs to prevent more
infections is in everyone’s interest, especially because most
international travelers to malaria-endemic areas do not take
any chemoprophylaxis. We intend this editorial to promote
exploration of the issues raised herein and as a means of
promoting discussion between tropical medicine and travel
physicians, drug regulatory authorities, pharmaceutical com-
panies, and the traveling public to change antimalarial drug
efficacy (which is already high) into effectiveness (which is
clearly suboptimal).
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